Future comprehensive intervention measures that target every aspect of CD63+ CAF activity from CD63+ CAFs to exosomal miR‐22 hold promising therapeutic potential to enhance tamoxifen sensitivity and further improve the outcomes of ERα‐positive breast cancer patients. The gene discussed is CD63; the disease is breast cancer.